

Table 7 Estimated costs of pneumococcal diseases with and without PCV-13, and discounted economic benefits^a of PCV-13 for 10 cohorts vaccinated over the period 2014–2023

Variable	Estimated costs (US\$)		
	No vaccine (current status)	PCV-13	Averted
Total government health service costs (× 1000)	127 854	82 315	45 540
Total outpatient visit costs	13 825	10 184	3 642
All-cause acute otitis media	13 212	9 796	3 416
Pneumococcal pneumonia	602	381	221
Pneumococcal meningitis	1.2	0.8	0.4
Pneumococcal NPNM	9 828	6 217	3 611
Total inpatient admissions	114 029	72 131	41 898
Pneumococcal pneumonia cases	77 717	49 161	28 556
Pneumococcal meningitis	5 393	3 411	1 981
Pneumococcal NPNM	30 920	19 559	11 361
Total society health service costs (× 1000)	447 780	295 463	152 318
Total outpatient visit costs	104 770	77 251	27 518
All-cause acute otitis media	100 831	74 760	26 071
Pneumococcal pneumonia	3 886	2 458	1 428
Pneumococcal meningitis	6.6	4.2	2.4
Pneumococcal NPNM	47	30	17
Total inpatient admissions	211 858	134 014	77 844
Pneumococcal pneumonia	163 537	103 448	60 089
Pneumococcal meningitis	7 503	4 746	2 757
Pneumococcal NPNM	40 818	25 820	14 998
Total sequelae costs	131 154	84 198	46 956
Major sequelae (single)	107 259	68 858	38 401
Major sequelae (multiple)	23 894	15 340	8 555

PCV = pneumococcal conjugate vaccine; NPNM = non-pneumonia, non-meningitis, and other diseases except sepsis.

^aCosts were discounted at 3% a year.